肝刺激因子对肝癌细胞增殖的调节作用

初断乳雄性ＳＤ大鼠的肝匀浆以超速离心和柱层析法分离纯化肝刺激因子（ＨＳＳ）,观察其对肝癌细胞增殖、细胞表皮生长因子（ＥＧＦ）受体表达及受体磷酸化的影响。结果表明,ＨＳＳ具有明显的促肝癌细胞分裂增殖能力,提高细胞周期中Ｓ期细胞所占比例。ＨＳＳ促肝癌细胞增殖作用与其促ＥＧＦ受体表达有关,表现为：（１）ＨＳＳ上调７０ｋＤ ＥＧＦ受体蛋白表达,此作用与ＥＧＦ合用后明显加强,即呈协同效应;（２）ＨＳＳ上调Ｅ     

肝刺激因子对人肝癌细胞BEL—7402p21^ras表达的影响

从雄性初断乳ＳＤ大鼠肝匀浆中提取肝刺激因子（ＨＳＳ）并加以部分纯化,观察其促人肝癌细胞增殖活性及对ｐ２１＾ｒａｓ蛋白表达的影响。结果表明：⑴ＨＳＳ具有明显的促人肝癌细胞增殖活性,其分子量为１４－２０ｋＤ;⑵ＨＳＳ可提高ｐ２１＾ｒａｓ蛋白表达,具有时间－效应关系,并与ＥＧＦ呈协同作用;⑶ＨＳＳ调节ｐ２１＾ｒａｓ蛋白表达具有剂量－效应关系,且呈现出饱和性。鉴于我们已报道ＨＳＳ上调ＥＧＦ受体蛋白和基因表     

转Bt基因棉花及其受体品种主要挥发性物质的测定

应用顶空进样气质联机系统（Headspace-GC-MS)测定了转Bt基因棉花及其对照亲本主要挥发性物质。结果表明棉花营养器官和繁殖器官的主要挥发性物质的差异,棉花植株现蕾期前,叶片中挥发性物质以α-蒎烯为主,而现蕾后,蕾、花和铃中主要以β-月桂烯为主。研究初步发现,外源Bt杀虫蛋白表达对棉花自身主要挥发性物质的合成不会造成不利影响。     

猪肝刺激物质pHSS对离体肝细胞DNA合成的影响

应用[~3H]TdR掺入离体培养大鼠肝细胞DNA的方法,测定由本室提取的pHSS的生物活性。结果表明,pHSS可显著促进原代培养大鼠肝细胞的DNA合成,其促进率约为对照组的10倍左右。培养液中血清浓度对pHSS的生物活性表达有显著影响,不同浓度血清可以使pHSS表现出不同的量效关系,这些结果在Buffello大鼠肝细胞系的实验中得到进一步证实。在低剂量pHSS的刺激下,不同年龄大鼠肝细胞的[~3H]TdR掺入率无显著差异。但高剂量时,pHSS对幼鼠作用不明显。     

新生牛肝脏再生刺激物质的部分纯化及生物学特性

新生牛肝胞浆液中存在刺激肝细胞DNA合成的物质,经过一定的分离提纯,可使其杂蛋白含量降低770倍,特异活性提高26.7倍。在无血清培养条件下,可使成年原代大鼠肝细胞和肝源性肿瘤细胞DNA合成分别增加5倍及7.2倍左右。HSS为耐热的蛋白质,一定的酸碱及变性剂可使活性丧失,主要活性成分的分子量在43—67KD之间,但小于10KD的物质亦具有一定的活性。该实验结果提示:HSS很可能是正常肝细胞分裂与再生时共同的调节因子。     

HPI在肝癌组织中的表达及其对肝癌细胞特异性抑增殖效应研究

肝细胞增殖抑制因子（Ｈｅｐａｔｉｃｐｒｏｌｉｆｅｒａｔｉｏｎｉｎｈｉｂｉｔｏｒ,ＨＰＩ）粗制品、半纯品和纯品对体外培养的人肝癌细胞具有显著抑增殖作用,随样品纯度提高抑制活性逐渐增强。纯品（浓度５μｇ／ｍｌ）的抑制率达７７．７１％。正常成年大鼠肝细胞呈ＨＰＩ阳性表达。在ＤＥＮ诱发大鼠肝细胞癌的发生发展过程中,转化的癌前期细胞和肝癌细胞呈ＨＰＩ阴性表达。表明肝细胞ＨＰＩ的表达能力在其癌变过程中消失,从而失去了自身的抑癌作用。     

CXCL1 在原发性肝癌中的表达及对人肝癌HepG2细胞增殖的影响

目的:探究CXCL1在原发性肝癌中的表达及对人肝癌HepG2细胞增殖的影响。方法:应用免疫组织化学技术(SP二步法)检测48例原发性肝癌组织、13正常肝脏组织中CXCL1表达情况;通过CCK8试剂盒检测CXCL1对HepG2细胞增殖能力的影响。结果:CXCL1在77.1%的原发性肝癌组织中表达,同时CXCL1在原发性肝癌组织中的表达高于正常肝脏组织,差异有统计学意义(P0.01);不同浓度CXCL1处理人肝癌HepG2细胞后,人肝癌HepG2细胞增殖能力明显增强,并且在一定范围内存在明显的剂量效应。结论:CXCL1在原发性肝癌中表达上调;CXCL1能够促进人肝癌HepG2细胞增殖。     

人肝刺激因子对大鼠实验性慢性肝损伤的保护作用

从健康孕妇水囊引产４─６个月龄的胎儿取肝,采用ＬａＢｒｅｃｑｕｅ方法提取人肝刺激因子（ｈＨＳＳ）。经３Ｈ－胸腺嘧啶核苷参入肝ＤＮＡ法测定其生物活性。表明此ｈＨＳＳ可刺激肝细胞ＤＮＡ合成。采用皮下注射ＣＣｌ４和饮用１０％乙醇来制备慢性肝损伤动物模型,观察了ｈＨＳＳ的保护肝脏作用。结果表明：ｈＨＳＳ可使ＣＣｌ４－乙醇所致慢性肝损伤大鼠的死亡率、血清谷丙转氨酶水平、肝组织中羟脯氨酸含量的升高以及肝组织中丙二醛的含量降低。肝组织切片表明：ｈＨＳＳ能减轻肝组织的损伤程度,促进肝细胞再生,并能明显防止肝纤维化的形成和发展。可见,ｈＨＳＳ对ＣＣｌ４－乙醇所致的慢性肝损伤大鼠有明显的保护作用,其机制可能与促进肝细胞再生及抑制肝细胞膜的脂质过氧化有关。     

鲨肝刺激物质类似物在大肠杆菌中的高密度发酵

为建立重组鲨肝刺激物类似物(r-sHSA)的高密度发酵方法,本研究在利用单因素实验和均匀设计实验优化摇瓶发酵培养基的组成和浓度以及诱导剂(IPTG)浓度的基础上,利用5L发酵罐进行了放大试验,探讨了补料方式、补料培养基的组成和浓度、诱导剂加入时间和诱导后菌体的收获时间对工程菌生物量和r-sHSA产量的影响。结果表明:在改良LB培养基(0.97%甘油,0.91%酵母粉,0.72%胰蛋白胨,0.782%KH2PO4,0.267%K2HPO4·3H2O,0.062%MgSO4·7H2O,0.5%NaCl,pH7.0)中,当pH控制在7.0、溶氧浓度为25%～30%的前提下,采用指数补料方式加入优化后的补料培养基(620g/L甘油,94.8g/L胰蛋白胨,3.3mL/L微量元素,7.5g/LMgSO4·7H2O)进行培养,在工程菌的OD600达到23时,加入终浓度为0.5mmol/L的IPTG诱导6h后收获菌体,菌体的生物量可达(123.27±1.184)g/L,r-sHSA产量为(2.662±0.041)g/L,比优化前提高了13.7倍。     

抑癌基因p16对人肝癌细胞生长抑制的机制研究

目的：探讨抑癌基因p16对肝癌细胞生长的抑制作用及其机制。方法：将p16cDNA亚克隆至pcDNA3．1真核表达载体上,并经脂质体介导转染至人肝癌细胞株SMMC-7721：用MTT法和Western blot分析转染细胞的生长情况。结果：成功构建重组表达质粒pcDNA3．1-p16,转染pcDNA3．1-p16的SMMC-7721细胞生长速度受到明显抑制;转染后有外源p16蛋白的表达,且伴随Bax上调,Bcl-2和cIAP2的下调。结论：重组pcDNA3．1-p16质粒能在人肝癌细胞SMMC-7721内表达,且能抑制SMMC-7721的生长,其机理与诱导肿瘤细胞凋亡相关。     

肝刺激因子对人肝癌细胞BEL -7402p21~(ras)表达的影响

从雄性初断乳SD大鼠肝匀浆中提取肝刺激因子 (HSS)并加以部分纯化 ,观察其促人肝癌细胞增殖活性及对p2 1ras蛋白表达的影响。结果表明 :(1)HSS具有明显的促人肝癌细胞增殖活性 ,其分子量为 14～ 2 0kD ;(2 )HSS可提高p2 1ras蛋白表达 ,具有时间 效应关系 ,并与EGF呈协同作用 ;(3)HSS调节p2 1ras蛋白表达具有剂量 效应关系 ,且呈现出饱和性。鉴于我们已报道HSS上调EGF受体蛋白和基因表达这一事实 ,本实验结果进一步说明 ,HSS促人肝癌肝细胞增殖与其调节EGF受体介导的信号分子传导过程相关。     

重组人肝刺激物在原核细胞中的表达与纯化

利用基因重组技术 ,构建成人肝刺激因子 (hHSS)和谷胱甘肽转移酶 (GST)融合表达载体 ,转化大肠杆菌BL 2 1(DE3 ) ,以His·Tag亲和层析纯化表达产物 ,FactorXa切割分离hHSS单体 ,并检测其生物学活性。结果显示 ,在pET 4 2a表达体系中hHSS以可溶性蛋白和包涵体两种形式存在 ,GST hHSS表达量占菌体可溶性蛋白的3 0 % ;FactorXa切割GST与hHSS之间肽腱 ,得到 3 3和 15kD两条蛋白带 ,经Western杂交证实 3 3kD条带为GST ,而 15kD条带的分子量与hHSS基因序列推测蛋白结果相符。经His·Tag再次纯化可获得hHSS单体 ,初步证实重组hHSS具有促进肝癌细胞增殖活性     

Growth induction of hepatic stimulator substance in hepatocytes through its regulation on EGF receptors

The cytosolic liver-specific growth factor-hepatic stimulator substance (HSS) has been shown to be able to amplify the rat hepatkocyte proliferation responded to BGF.In order to get more insight into the mechanism,the regulatory effect of HSS on EGF-receptor (EGF-R) and the receptor phosphorylation at molecular level was studied.HSS partially purified from weanling rat liver was given to cultured hepatocytes and its influence on EGF-R specific binding and internalization as well as mRNA expression were investigated.The results showed that preincubation of hepatocytes with HSS could lead to an increase in [^125I]-EGF binding to its receptors and inhibit EGF-induced receptor down-regulation.Furthermore,the overexpression of EGF-R mRNA stimulated by HSS was seen during 2-12 h after the incubation.Additionally,it was demonstrated with human hepatoma SMMC-7721 cells in Western blot that the EGF-R expression and the receptor autophosphorylation were increased with dose/timedependency after HSS treatment.These results strongly suggest that the mechanism of HSS action on hepatocyte growth might be related to its modulation on EGF-R and receptor-mediated signaling transfuction.     

Effects of shark hepatic stimulator substance on the function and antioxidant capacity of liver mitochondria in an animal model of acute liver injury

This study was carried out to investigate whether shark hepatic stimulator substance （HSS） can prevent acute liver injury and affect mitochondrial function and antioxidant defenses in a rat model of thioacetamide （TAA）-induced liver injury. The acute liver injury was induced by two intraperitoneal injections of TAA （400 mg/kg） in a 24 h interval. In the TAA plus shark HSS group, rats were treated with shark HSS （80 mg/kg） 1 h prior to each TAA injection. In this group, serum liver enzyme activities were significantly lower than those in the TAA group. The mitochondrial respiratory control ratio was improved, and the mitochondrial respiratory enzyme activities were increased in the TAA plus shark HSS group. The mitochondrial antioxidant enzyme activities and glutathione level were higher in the TAA plus shark HSS group than in the TAA group. These results suggest that the protective effect of shark HSS against TAA-induced acute liver injury may be a result of the restoration of the mitochondrial respiratory function and antioxidant defenses and decreased oxygen stress.     

Effects of basic fibroblast growth factor on angiogenin expression and cell proliferation in H7402 human hepatoma cells

Hepatocellular carcinoma （HCC） is one of the most common cancers worldwide. Basic fibroblast growth factor （bFGF）, which is highly expressed in developing tissues and malignant cells, regulates cell growth, differentiation, and migration. Its expression is essential for the progression and metastasis of HCC. This study aims to investigate the effects of bFGF on the expression of angiogenin, another growth factor, which plays an important role in tumor angiogenesis, and on cell proliferation in H7402 human hepatoma cells. The bFGF sense cDNA or antisense cDNA was stably transfected into H7402 cells. Genomic DNA PCR analysis demonstrated that human bFGF sense cDNA or antisense cDNA was inserted into the genome. Furthermore, the expression of bFGF and angiogenin was examined by RT-PCR and Western blot assays. MTT and colony formation assays were employed to determine cell proliferation. Stable bFGF over-expressing and under-expressing transfectants were successfully established. Expression of angiogenin was decreased in the over-expressing bFGF cells （sense transfectants） and was increased in the under-expressing bFGF cells （antisense transfectants）. Cell proliferation increased in the bFGF sense transfectants and decreased in the bFGF antisense transfectants. These results demonstrated that the endogenous bFGF may not only negatively regulate the angiogenin expression but also contribute to the overall cell proliferation in H7402 human hepatoma cells. This study may be helpful in finding a potential therapeutic approach to HCC.     

大鼠纤维化肝组织中SHP1表达与肝星状细胞活化及增殖的关系*

目的: 探讨大鼠肝纤维化病理过程中肝组织及在体肝星状细胞 (HSC)的含SH2结构域的蛋白酪氨酸磷酸酶1 (SHP1)表达变化与在体HSC活化及增殖的关系。方法: 随机将50只健康雄性SD大鼠分为对照组(10只)、模型组(40只),采用腹腔注射四氯化碳法建立大鼠肝纤维化模型,Masson三色染色及HE染色检测大鼠肝脏组织的病理组织学变化,SHP1与α-平滑肌肌动蛋白 (α-SMA)免疫荧光双标记检测大鼠肝组织中活化HSC的SHP1表达,免疫组织化学染色检测大鼠肝组织的α-SMA及SHP1表达,并分别对大鼠肝组织的SHP1表达及大鼠肝组织中活化HSC的SHP1表达与大鼠肝组织的α-SMA表达进行Pearson’s相关性分析。结果: 大鼠肝纤维化模型成功构建,随着造模时间延长,大鼠肝纤维化逐渐加重。与对照组大鼠肝组织的SHP1阳性表达平均光密度值 (MOD) (0.08±0.01)比较,造模不同时间(2周、4周、6周、8周)大鼠纤维化肝组织的SHP1阳性表达MOD (0.11±0.01、0.14±0.01、0.16±0.01、0.19±0.01)显著增加(P＜0.05),并逐渐升高(P＜0.05)。与对照组大鼠肝组织的α-SMA阳性表达MOD (0.04±0.01)比较,造模不同时间(2周、4周、6周、8周)大鼠纤维化肝组织的α-SMA阳性表达MOD (0.06±0.01、 0.09±0.01、0.12±0.01、0.16±0.02)明显增加(P＜0.05),并逐渐升高(P＜0.05),即在体HSC的活化及增殖逐渐加快(α-SMA是HSC的活化标志)。SHP1与α-SMA免疫荧光双标记检测显示,造模2周、4周、6周、8周大鼠纤维化肝组织中表达SHP1的活化HSC占总的活化HSC的百分比(26.49%±3.44%、37.14%±4.57%、44.90%±2.94%、58.09%±5.33%)逐渐升高(P＜0.05)。上述大鼠纤维化肝组织的SHP1表达及大鼠纤维化肝组织中表达SHP1的活化HSC占总的活化HSC的百分比均与大鼠纤维化肝组织的α-SMA表达呈显著正相关(r值为0.926, 0.984,P＜0.05)。结论: 在大鼠肝纤维病理过程中,肝组织及在体HSC 的SHP1表达与在体HSC的活化及增殖呈显著正相关。